NeoCardial Technologies, LLC

NeoCardial was formed by an experienced and historically successful team comprising highly skilled medical, scientific, engineering, and entrepreneurial individuals who are determined to evolve the cardiac treatment landscape by prolonging the lives of those who have succumbed to heart failure in a way that will enable maintenance of heart function, produce or augment functional recovery, and allow a comfortable lifestyle. Currently, there is neither a pharmaceutical nor a proven technology available that achieves all of those goals in patients with advanced heart failure.

The NeoCardial team has developed a minimally-invasive non-blood contact extra-ventricular assist device (eVAD) that surrounds the surface of heart and through mild direct compression, augments the pumping of blood volume from the ventricles. Our eVAD does not require incising for intracardiac placement, further damaging the heart, as existing VAD’s do, and does not require direct blood contact, as existing VAD’s also do; instead, it embraces the pumping chambers of the heart and, through rhythmic contractions, enables the heart itself to sustain the crucial pumping efficacy of blood from the ventricles. The NeoCardial eVAD operates bi-ventricularly and can apply or modify pressure at different levels to each ventricle. Presently, the NeoCardial team is refining and miniaturizing the NeoCardial eVAD, planning, ultimately, to have it work remotely. Pre-clinical animal work has confirmed our intended premise: success in achieving enhanced heart function in the advanced failing heart.

Once product finalization and pre-clinical work are completed, NeoCardial will seek the regulatory approvals necessary for conducting clinical work on humans. FDA approval for marketing will follow.